| Pharmaceutical Information |
| Drug Name |
Isavuconazonium |
| Drug ID |
BADD_D02455 |
| Description |
Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA for the treatment of invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns of nephrotoxicity associated with cyclodextrin. Isovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market. |
| Indications and Usage |
Indicated in the treatment of invasive aspergillosis and invasive mucormycosis. |
| Marketing Status |
Not Available |
| ATC Code |
Not Available |
| DrugBank ID |
DB06636
|
| KEGG ID |
D10644
|
| MeSH ID |
Not Available
|
| PubChem ID |
6918606
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
Not Available |
| Synonyms |
Not Available |
|
| Chemical Information |
| Molecular Formula |
C35H35F2N8O5S+ |
| CAS Registry Number |
742049-41-8 |
| SMILES |
CC(C1=NC(=CS1)C2=CC=C(C=C2)C#N)C(CN3C=[N+](C=N3)C(C)OC(=O)N(C)C4=C(C=CC=N4)COC(=
O)CNC)(C5=C(C=CC(=C5)F)F)O |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
